Three New Triterpenoid Saponins from the Seeds of Aesculus chinensis

Jing ZHAO, Xiu Wei YANG*, Yu Xin CUI, Xue Hui LIU

National Laboratory of Natural and Biomimetic Drugs, Beijing Medical University, Beijing 100083

Three new triterpenoid saponins, escins IVc (1), IVd (2) and IVf (3) were isolated of chinensis. They from the Aesculus were determined seeds 22α -tigloyl-28-acetylprotoaescigenin- 3β -O- [β -D-glucopyranosyl ($1\rightarrow 2$)] [β -D-glucopyranosyl acid 1, 22α-angeloyl-28-acetylprotoaescigenin-3β-O- $(1\rightarrow 4)$]- β -D-glucopyranosiduronic [β-D-glucopyranosyl (1 \rightarrow 2)] [β-D-glucopyrano- syl (1 \rightarrow 4)]-[β-D-glucopyranosiduronic acid **2** and 28-tigloyl protoaescigenin-3 β -O- [β -D-gluco-pyranosyl (12)] [β -D-glucopyranosyl (1 \rightarrow 4)] -β-D-glucopyranosiduronic acid 3.

Keywords: Triterpenoid saponins, Aesculus chinensis, escins IVc, IVd and IVf.

In previous papers we have reported the isolation and identification of escins Ia, Ib, IVa, IVb and IVe^{1, 2}. Now we describe the structure elucidation of three more new triterpenoid saponins, named escins IVc (1), IVd (2) and IVf (3).

Compound 1 was isolated as white amorphous powder. HR-SI-MS revealed the composition of C₅₅H₈₆O₂₄ by molecular ion peak at m/z 1129.5438. Compared with the ¹³C and ¹H NMR spectra of escin Ia, compound 1 is also a glycoside of protoaescigenin acylated by the tigloyl and the acetyl group. The significant differences between them were the chemical shifts of C-21 (δ76.2) and C-22 (δ77.9) with the corresponding protons at δ4.95 and 5.92. In addition, minor changes were also observed for C-17 (δ45.9), C-18 (δ41.4) and H-18 (δ2.75). The stereochemistry of C-21 and C-22 remained unchanged as demonstrated by NOESY spectrum: Me-29 showed a strong NOE correlation with H-21 while Me-30 correlated with H-22 strongly. This was consistent with escin Ia. The attachments of the tigloyl group at C-22 and the acetyl group at C-28 were derived from HMBC experiment, which correlated the carbonyl carbons of the tigloyl and the acetyl group to H-22 (δ 5.92) and H-28 (δ 4.02) respectively. In addition, the number of monosaccharides in the structure was suggested by three anomeric carbon resonances at $\delta 104.4$, 104.0 and 104.4 with the corresponding anomeric protons at δ4.87, 5.58 and 5.18. ¹H and ¹³C NMR signals of the trisaccharide moiety were coincident with those of escin Ia^{1, 3}. And acid hydrolysis of compound 1 also yielded glucose and glucuronic acid. Their sequences and linkage sites were further confirmed by HMBC correlations between the following pairs: C-3 (δ90.9) and H-1' $(\delta 4.87)$; C-2' $(\delta 79.5)$ and H-1" $(\delta 5.58)$; and C-4' $(\delta 81.7)$ and H-1" $(\delta 5.18)$. Hence,

compound 1 was established as 22α -tigloyl-28-acetylprotoaescigenin-3 β -O-[β -D-glucopyranosyl (1 \rightarrow 2)] [β -D-glucopyranosyl (1 \rightarrow 4)] - β -D-glucopyranosiduronic acid, and named escin IVc.

Figure 1. Structures of Compounds 1~3

Compound **2** was determined to be an isomer of **1**. HRMALDI MS showed the quasimolecular ion peak at m/z 1153.5406 [M+Na]⁺, consistent with the molecular formula of $C_{55}H_{86}O_{24}$. The only differences between them in 1H and ^{13}C NMR spectra were signals due to an angeloyl group [^{13}C NMR: $\delta 168.1$ (C-1""), 129.1 (C-2""), 136.6 (C-3""), 15.7 (C-4"") and 20.6 (C-5""); 1H NMR: $\delta 5.83$ (H-3""), 1.43 (Me-4"") and 1.92 (Me-5"")] replaced those due to a tigloyl group. Similar HMBC and NOE correlations were also present for **2**. Therefore, compound **2** was identified as 22α -angeloyl-28-acetyl-protoaescigenin-3 β -O- [β -D-glucopyranosyl (1 \rightarrow 2)] [β -D-gluco-pyranosyl (1 \rightarrow 4)] - β -D-glucopyranosiduronic acid, and named escin IVd. Compounds **1** and **2** are geometrical isomers.

Table: 13 C NMR Spectral Data of Compounds **1-3** (δ Relative to TMS in pyridine- d_5 , 125MHz)

C	1	2	3	С	1	2	3
1	38.2	38.2	38.3	1'	104.4	104.3	104.5
2	26.3	26.3	26.3	2'	79.4	79.5	79.5
3	90.9	90.8	90.8	3'	76.2	76.6	76.6
4	43.4	43.4	43.4	4'	81.7	81.4	82.7
5	55.8	55.8	55.9	5'	75.5	75.5	76.6
6	18.3	18.3	18.3	6'	171.5	171.9	174.4
7	32.9	32.8	33.0	1"	104.0	104.0	104.0
8	39.6	39.6	39.7	2"	75.5	75.5	75.4
9	46.5	46.5	46.5	3"	78.3	78.0	78.2
10	36.1	36.1	36.1	4"	69.5	69.5	69.5
11	23.8	23.8	23.9	5"	78.1	77.8	77.8
12	123.0	123.0	123.2	6"	61.3	61.3	61.3
13	142.3	142.2	143.1	1""	104.4	104.3	104.2
14	41.5	41.5	41.7	2""	74.7	74.7	74.8
15	34.4	34.4	34.6	3'''	78.1	78.3	78.0
16	67.7	68.0	68.0	4'''	71.3	71.3	71.2
17	45.9	45.7	46.6	5'''	77.8	77.8	77.6
18	41.4	41.3	40.7	6'''	62.2	62.2	62.0
19	47.2	47.2	47.6	1""	168.1	168.1	167.6
20	36.6	36.7	36.2	2""	129.6	129.1	128.0
21	76.2	76.1	75.4	3""	136.2	136.6	138.1
22	77.9	77.8	73.4	4""	13.8	15.7	15.8
23	22.3	22.2	22.3	5""	12.2	20.6	20.8
24	63.1	63.0	63.1	1"""	170.8	170.7	
25	15.4	15.3	15.4	2"""	20.6	20.7	
26	16.5	16.5	16.7				
27	27.2	27.3	27.3				
28	68.4	68.2	66.4				
29	30.0	30.0	30.4				
30	19.2	19.2	19.2				

Compound 3 was elucidated by comparison with escin IVe² {28-tigloyl protoaescigenin-3 β -O- [β -D-glucopyranosyl (1 \rightarrow 2)] [β -D-glucopyranosyl (1 \rightarrow 4)] - β -D-glucopyranosiduronic acid}. Negative-ion HRSIMS showed a quasimolecular ion peak at m/z 1087.5319, consistent with the molecular composition of $C_{53}H_{84}O_{23}$. The 1H and ^{13}C NMR signals belonging to an angeloyl group instead of a tigloyl group were observed. HMBC experiment also identified C-28 esterification of the angeloyl group and the identical structure of the trisaccharide. With all the above evidences, compound 3 was established as 28-angeloylprotoaescigenin-3 β -O- [β -D-glucopyranosyl (1 \rightarrow 2)] [β -D-glucopyranosyl (1 \rightarrow 4)] - β -D- glucopyranosiduronic acid, and named escin IVf. It is a geometrical isomer of escin IVe.

References

- J. Zhao, X. W. Yang, Y. X. Cui, X. H. Liu, S. Y. Liu, H. Y. Zhi, J. Y. Chen, F. B. Zhu,
- Z. X. Jiang, Y. L. Xue and D. B. Liu, *Chin. Chem. Lett.*, **1999**, (accepted).
 J. Zhao, X. W. Yang, Y. X. Cui and X. H. Liu, *Chin. Chem. Lett.*, **1999**, (accepted).
 M. Yoshikawa, T. Murakami, H. Matsuda, J. Yamahara, N. Murakami, I. Kitagawa, *Chem. Pharm. Bull.*, **1996**, *44*(8), 1454.

Received 12 April 1999